Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec Achieves Third Sanofi Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec Achieves Third Sanofi Milestone

Meets pre-agreed critical criteria within the beta cell replacement therapy program under diabetes research alliance

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec SE has successfully achieved a third milestone in its diabetes research alliance with Sanofi (TargetBCD), resulting in a €3 million payment to Evotec.

Evotec met pre-agreed critical criteria within the beta cell replacement therapy program. The goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells.

Dr. Cord Dohrmann, chief scientific officer of Evotec, said, “We are extremely pleased with the progress we are making on this beta cell therapy approach which has the potential to restore beta cell function and, thereby, address the root cause of diabetes rather than only its symptoms.”
 
The companies entered the research alliance in August 2015 to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells for diabetes. Both companies have made significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration extends Evotec’s metabolic disease and stem cell-based drug discovery programs. To date, Evotec has received €12 million in upfront and milestone payments from Sanofi, as well as substantial research funding.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics